Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx, Scienion Partner to Commercialize Nanowire Biosensor

NEW YORK (GenomeWeb) – QuantuMDx and German microarray firm Scienion today announced that they have partnered to commercialize QuantuMDx's multiplexed nanowire array technology.

The nanowire technology is a component of QuantuMDx's Q-Poc handheld molecular diagnostic device. Molecular probes are printed on each nanowire in the array, raising multiplex potential.

The firms said in a statement that QuantuMDx has purchased Scienion's sciFlexarrayer SX, and that they will use this ultra-low-volume liquid handling technology to transfer biological material onto QuantuMDx's biosensor.

The firms also said they will launch several development projects as they push to begin mass manufacturing the nanowire biosensor.

In March Scienion's microarray manufacturing process received ISO 13485 certification

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.